Browse the evidence

Weight loss interventions in women with breast cancer significantly reduced body weight and fat mass but also reduced lean mass.

Practitioners should be aware that while weight loss interventions can be effective, they may also lead to reductions in lean mass.

ATP supplementation has been reported to result in positive effects on muscle mass, strength, and power gains.

ATP supplementation may be beneficial for enhancing muscle performance metrics.

Obesity is a leading risk factor for cardiovascular disease (CVD).

Clinicians should prioritize addressing obesity to mitigate CVD risks.

Obesity contributes to the emergence of cardiovascular risk factors such as dyslipidaemia, type 2 diabetes, hypertension, and sleep disorders.

Addressing obesity may help in managing these associated cardiovascular risk factors.

Some researchers claim that the timing of nutritional consumption may be more critical to muscle development than the absolute daily consumption of nutrients.

Practitioners should consider the potential importance of nutrient timing in relation to total daily intake for muscle development.

Semaglutide and tirzepatide show therapeutic potential as cardioprotective and nephroprotective agents.

Practitioners can consider semaglutide and tirzepatide for patients at risk of cardiovascular and renal diseases.

The GLP-1RA/GIPR antagonist MariTide achieved substantial reductions in weight and HbA1c.

MariTide may be an effective option for weight management and glycemic control in patients.

Women who were obese at both 20 years old and currently, as well as those who became obese, have a similar high risk of non-communicable diseases (NCDs).

Practitioners should be aware that both persistent and newly obese women are at high risk for NCDs.

Leisure time physical activity attenuates the negative effects of obesity on non-communicable diseases, particularly for consistently obese women.

Encouraging physical activity can help mitigate health risks associated with obesity.

The prevalence of non-communicable diseases among women who were no longer obese is similar to that of consistently non-obese women.

Weight loss may lead to similar health outcomes as never being obese.

A national 10% tax on sugar-sweetened beverages and processed meats would prevent a total of 33,700 CMD deaths/year.

Implementing a 10% tax on unhealthy foods could significantly reduce CMD mortality.

A SNAP-targeted 30% subsidy for healthy foods would offer the largest reductions in CMD mortality and disparities.

Targeted subsidies for healthy foods could greatly reduce CMD mortality and health disparities.

Specific population interventions can effectively improve diet and may be cost-effective.

Implementing targeted dietary interventions can lead to better health outcomes and may save costs.

Selected policy interventions may reduce health disparities.

Policymakers should consider dietary interventions as a means to promote health equity.

Current pharmacotherapy options for obesity include agents like liraglutide, semaglutide, and tirzepatide.

Practitioners should be aware of these specific pharmacotherapy options for treating obesity.

Novel therapies, including dual and triple incretin agonists, are under investigation for obesity treatment.

Practitioners should stay informed about emerging therapies that may enhance obesity treatment.

Bariatric surgery before liver transplantation is feasible and can improve liver function for patients on the transplant waiting list.

Bariatric surgery may be a beneficial option for patients with obesity awaiting liver transplantation to enhance liver function.

The consensus defines sarcopenic obesity with a 3-step algorithm, including screening, diagnosis, and intervention.

Practitioners can use this algorithm for diagnosing and managing sarcopenic obesity.

Multidomain lifestyle intervention may slow biological aging long term, as captured by an FI-E.

Practitioners may consider recommending multidomain lifestyle interventions to promote long-term health benefits.

FI-E scores were relatively lower among lifestyle participants throughout follow-up.

Lifestyle interventions may be effective in reducing frailty over time.

Male participants experienced greater effects than females (P < 0.001).

Practitioners should consider gender differences when designing resistance training programs.

Tirzepatide was evaluated for its effects on cardiovascular and diabetic kidney disease biomarkers in overweight and obese adults with type 1 diabetes over a period of 21 months.

Practitioners may consider tirzepatide for managing cardiovascular and kidney health in overweight and obese patients with type 1 diabetes.

Maximal voluntary contraction (MVC) of the knee extensors was significantly greater in younger adults (256 ± 72 N·m) compared to older adults (137 ± 48 N·m), P < 0.001.

Younger adults demonstrate greater knee extensor strength, which may influence exercise programming for older adults.

Relative quadriceps muscle EMG activity was significantly higher in older adults compared to younger adults across all exercise tasks (P < 0.01).

Older adults may require different training approaches to optimize muscle activation.